ArticleInternational journal of general medicine2025
Predictive Value of the COP-INH Score for Adverse Cardiovascular Events After PCI in ACS Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) require long-term antiplatelet therapy to prevent in-stent restenosis. However, the efficacy of this treatment can be compromised by factors, such as aspirin resistance and variable clopidogrel reactivity, potentially leading to adverse clinical outcomes. This study aims to assess the clinical significance of detecting platelet reactivity to P2Y12 receptor inhibitors and platelet inhibition rates in patients with ACS post-PCI and assessing the relation of the occurrence of major adverse cardiac events (MACE). Methods: We employed the VerifyNow P2Y12 system to assess platelet reactivity to P2Y12 receptor inhibitors and platelet inhibition rates. The combination of P2Y12 reaction unit and percentage of platelet inhibition [%INH] (COP-INH) score was calculated 30 days post-PCI for patients with ACS. The primary endpoint events included cardiovascular death, non-fatal myocardial infarction, and target vessel revascularization at 1-year follow-up. We analyzed the correlation between the COP-INH score and primary endpoint events. Results: The incidence of major adverse cardiovascular events was significantly higher in patients with a COP-INH score of 2, compared with those with a score of 1 or 0 (20.31% vs 7.69%, Conclusion: The COP-INH score may serve as a potential predictor for long-term adverse cardiovascular events following PCI in patients with ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.